A subset of melanomas harbor non-BRAF p. V600E mutations in codon 600 or its proximity (e.g. p. L597Q & K601E)17–19, and studies have shown efficacy for targeted therapies in metastatic melanoma patients with mutations that affect other residues in BRAF20–23, albeit at a lower response rate compared to V600E mutated cases24. Here, BRAF is linked to metastatic melanoma.